ATE193020T1 - Verfahren zur herstellung von immunoglobulin g konzentrat - Google Patents

Verfahren zur herstellung von immunoglobulin g konzentrat

Info

Publication number
ATE193020T1
ATE193020T1 AT94918916T AT94918916T ATE193020T1 AT E193020 T1 ATE193020 T1 AT E193020T1 AT 94918916 T AT94918916 T AT 94918916T AT 94918916 T AT94918916 T AT 94918916T AT E193020 T1 ATE193020 T1 AT E193020T1
Authority
AT
Austria
Prior art keywords
concentrate
pct
immunoglobulin
sec
date
Prior art date
Application number
AT94918916T
Other languages
English (en)
Inventor
Miryana Burnouf
Dominique Dernis
Patrick Bonneel
Thierry Burnouf
Original Assignee
Aetsrn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aetsrn filed Critical Aetsrn
Application granted granted Critical
Publication of ATE193020T1 publication Critical patent/ATE193020T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94918916T 1993-06-14 1994-06-13 Verfahren zur herstellung von immunoglobulin g konzentrat ATE193020T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9307128A FR2706466B1 (fr) 1993-06-14 1993-06-14 Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
PCT/FR1994/000699 WO1994029334A1 (fr) 1993-06-14 1994-06-13 Concentre d'immunoglobulines g a usage therapeutique et procede de production dudit concentre

Publications (1)

Publication Number Publication Date
ATE193020T1 true ATE193020T1 (de) 2000-06-15

Family

ID=9448094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94918916T ATE193020T1 (de) 1993-06-14 1994-06-13 Verfahren zur herstellung von immunoglobulin g konzentrat

Country Status (16)

Country Link
US (1) US6069236A (de)
EP (1) EP0703922B1 (de)
JP (1) JP4218980B2 (de)
AT (1) ATE193020T1 (de)
AU (1) AU7002394A (de)
BR (1) BR9406814A (de)
CA (1) CA2165203C (de)
CZ (1) CZ287186B6 (de)
DE (1) DE69424545T2 (de)
DK (1) DK0703922T3 (de)
ES (1) ES2148332T3 (de)
FR (1) FR2706466B1 (de)
GR (1) GR3034177T3 (de)
HU (1) HU218463B (de)
PT (1) PT703922E (de)
WO (1) WO1994029334A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140155A (en) * 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
JP4685238B2 (ja) * 1998-06-09 2011-05-18 ツエー・エス・エル・ベーリング・アクチエンゲゼルシヤフト 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
US6962700B1 (en) 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP3087991A1 (de) 2003-11-08 2016-11-02 Prothera Biologics Zusammensetzung von inter-alpha-hemmer-proteinen aus plasma zur therapeutische verwendung
EP1532983A1 (de) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulinpräparationen mit erhöhter Stabilität
TWI391399B (zh) * 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
FR2895263B1 (fr) 2005-12-26 2008-05-30 Lab Francais Du Fractionnement Concentre d'immunoglobines g (lg) appauvri en anticorps anti-a et anti-b, et en igg polyreactives
WO2007136327A1 (en) * 2006-05-22 2007-11-29 Ge Healthcare Bio-Sciences Ab A method of producing igg
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
TR201808152T4 (tr) 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
FR2939667B1 (fr) 2008-12-17 2012-01-27 Fractionnement Et Des Biotechonologies Lab Franc Composition d'immunoglobine g comme medicament pour le traitement de l'ictere neonatal par incompatibilite foetomaternelle dans le systeme abo
MY157239A (en) 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
IT1397061B1 (it) 2009-12-28 2012-12-28 Kedrion Spa Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
JP6078344B2 (ja) 2010-02-04 2017-02-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリン製剤
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
RU2649363C2 (ru) 2010-11-16 2018-04-02 Октафарма Аг СПОСОБЫ СНИЖЕНИЯ И/ИЛИ УДАЛЕНИЯ FXI и FXIa ИЗ РАСТВОРОВ, СОДЕРЖАЩИХ УКАЗАННЫЕ ФАКТОРЫ СВЕРТЫВАНИЯ
SG191781A1 (en) 2010-12-30 2013-08-30 Lab Francais Du Fractionnement Glycols as pathogen inactivating agents
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
ES2647925T3 (es) * 2011-05-12 2017-12-27 Csl Behring Gmbh Métodos para reducir los eventos adversos causados por preparados farmacéuticos que comprenden proteínas derivadas del plasma
FR2977893B1 (fr) 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
MY165164A (en) 2011-08-26 2018-02-28 Baxalta Inc Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
DK2820042T3 (da) 2012-02-29 2019-10-28 Baxalta GmbH Igg-stimuleret remyelinisering af perifere nerver
EP2636681A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Verfahren zur Anreicherung von IgA
EP2636684A1 (de) 2012-03-09 2013-09-11 CSL Behring AG Vorbeugung von Infektionen
MX360245B (es) 2012-03-09 2018-10-26 Csl Behring Ag Composiciones que comprenden inmunoglobulinas de tipo secretor.
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
US10611826B2 (en) 2013-07-05 2020-04-07 Laboratoire Français Du Fractionnement Et Des Biotechnologies Affinity chromatography matrix
US9663553B2 (en) 2014-01-29 2017-05-30 Hemarus Therapeutics Limited Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
FR3018450B1 (fr) 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines
WO2015137530A1 (ko) * 2014-03-11 2015-09-17 주식회사 녹십자홀딩스 면역글로불린의 정제방법
US9556253B2 (en) * 2014-12-02 2017-01-31 Hemarus Therapeutics Limited Process for increased yield of immunoglobulin from human plasma
HUE052280T2 (hu) 2014-12-03 2021-04-28 Csl Behring Ag Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
US20190269765A1 (en) 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
FR3064484A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition d'immunoglobulines utiles pour traiter des infections virales
FR3064486A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Prevention d'une infection par le virus respiratoire syncytial dans les voies respiratoires superieures
FR3064485A1 (fr) 2017-03-31 2018-10-05 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Traitement d'une infection par le virus respiratoire syncytial
AU2018258466B2 (en) 2017-04-25 2025-05-22 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
CA3173539A1 (en) 2020-03-31 2021-10-07 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CN116802206A (zh) 2020-12-28 2023-09-22 等离子体技术有限责任公司 用于生产规模的免疫球蛋白g分离系统和方法
CA3203540A1 (en) * 2020-12-28 2022-07-07 Eugene ZURLO Systems and methods for process scale isolation of immunoglobulin g
EP4689667A1 (de) * 2023-03-29 2026-02-11 CSL Behring AG Verfahren zur identifizierung von mit nebenwirkungen assoziiertem immunglobulin
CN121985959A (zh) 2023-09-26 2026-05-05 武田药品工业株式会社 耗减IgA的免疫球蛋白制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7511055A (nl) * 1975-09-19 1977-03-22 Leuven Res & Dev Vzw Trombosetest.
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
ES8203612A1 (es) * 1981-06-04 1982-04-01 Landerlan Sa Lab Procedimiento de preparacion de imuno globulina g nativa li-bre de actividad anticomplementaria
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4841024A (en) * 1986-09-15 1989-06-20 Becton Dickinson And Company Purification of antibodies
DE3640513A1 (de) * 1986-11-27 1988-06-09 Biotest Pharma Gmbh Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
US4806346A (en) * 1986-12-16 1989-02-21 American Home Products Corporation Method for isolation of antigen specific immunoglobulin
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
DE4118912C1 (de) * 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
BR9406814A (pt) 2000-05-30
FR2706466B1 (fr) 1995-08-25
JPH09500369A (ja) 1997-01-14
WO1994029334A1 (fr) 1994-12-22
DK0703922T3 (da) 2000-11-13
PT703922E (pt) 2000-11-30
HU9503557D0 (en) 1996-02-28
EP0703922B1 (de) 2000-05-17
HU218463B (hu) 2000-09-28
ES2148332T3 (es) 2000-10-16
HUT74272A (en) 1996-11-28
FR2706466A1 (fr) 1994-12-23
DE69424545T2 (de) 2001-01-18
EP0703922A1 (de) 1996-04-03
US6069236A (en) 2000-05-30
CA2165203A1 (fr) 1994-12-22
JP4218980B2 (ja) 2009-02-04
CZ287186B6 (en) 2000-10-11
DE69424545D1 (de) 2000-06-21
CA2165203C (fr) 2009-08-18
CZ328795A3 (en) 1996-07-17
GR3034177T3 (en) 2000-11-30
AU7002394A (en) 1995-01-03

Similar Documents

Publication Publication Date Title
DE69424545D1 (de) Verfahren zur herstellung von immunoglobulin g konzentrat
DE59305526D1 (de) Verfahren zur herstellung von olefinen
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
ATE288447T1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
DE59003771D1 (de) Verfahren zur Herstellung von cyclischen Aminosäurederivaten sowie Zwischenprodukte.
DE69011859D1 (de) Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
ATE213252T1 (de) Verfahren zur herstellung eines inter-alpha- trypsin inhibitor konzentrats mit therapeutischer anwendung und so erhaltenes konzentrat
ATE232854T1 (de) Verfahren zur herstellung von 9-desoxotaxanen
ATE166230T1 (de) Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
ATE166881T1 (de) Verfahren zur herstellung von faktor viii
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE169641T1 (de) Verfahren zur herstellung von stärkeabbauprodukten
DE59606057D1 (de) Verfahren zur herstellung von dihydroxypyrimidin-derivaten
ATE174601T1 (de) Verfahren zur herstellung von bisnoraldehyden aus bisnoralkohol
FI973469A0 (fi) Menetelmä tekijän IX valmistamiseksi biologisista lähteistä
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE191457T1 (de) Verfahren zur herstellung von einem bicyclohexanderivat
EP0711159A4 (de) Verfahren und zusammensetzungen zur behandlung von asthma, arthereosklerose und entzuendlichen erkrankungen unter verwendung von optisch reinem (-)-zilenton
ATE171620T1 (de) Verwendung von verzweigtkettigen aminosäuren zur herstellung eines arzneimittels zur behandlung von tardiver dyskinesia
ATE185349T1 (de) Verfahren zur herstellung von dolastatin 15 und deren zwischenprodukten
ATE320263T1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69514512D1 (de) Verfahren zur herstellung von benzopyranderivaten
ATE210665T1 (de) Zwischenprodukte und verfahren zur herstellung von 5,6-dihydropyrrolo(2,3-d)pyrimidinen
DE59600460D1 (de) Verfahren zur Herstellung von tert.-Butylamin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner